OLYSIO® sales during the first quarter 2016

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 32 MUSD.

The royalty for the first quarter amounted to 18 MSEK (2.0 MEUR). Medivir’s royalties based on sales for the first quarter are calculated from the first royalty tier.

OLYSIO® global net sales Sales in MUSD
Market Q1 -2016 Q1-2015 Change
  US 16 98 -84%
  RoW 16 136 -88%
Total global net sales MUSD 32 234 -86%

Going forward royalty for OLYSIO® will be disclosed only in the interim reports and not announced separately, unless world-wide sales materially increase.

The Interim Report for January – March 2016 will be published on 28 April 2016, at 8.30 CET, followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 14:30 CET on 19thof April 2016.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe

Documents & Links